Hailshadow/iStock via Getty Images
- The European Commission has approved Merck’s (NYSE:MRK) Capvaxive (pneumococcal 21-valent Conjugate Vaccine) shot for pneumococcal disease and pneumococcal pneumonia.
- The vaccine provides protection against 21 Streptococcus pneumoniae serotypes.
- Approval was based on results from the phase 3 STRIDE program.
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/954822544/image_954822544.jpg?io=getty-c-w750
2025-03-26 08:16:16
